Ram Chuttani - 01 Aug 2023 Form 3 Insider Report for ALLURION TECHNOLOGIES, INC. (ALUR)

Role
Chief Medical Officer
Signature
/s/ Jennifer Ausrotas, attorney-in-fact
Issuer symbol
ALUR
Transactions as of
01 Aug 2023
Net transactions value
$0
Form type
3
Filing time
01 Aug 2023, 20:56:57 UTC
Next filing
06 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ALUR Common Stock 1,662,896 01 Aug 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ALUR Stock Option (Right to Buy) 01 Aug 2023 Common Stock 48,899 $1.13 Direct F1
holding ALUR Stock Option (Right to Buy) 01 Aug 2023 Common Stock 122,249 $1.13 Direct F1
holding ALUR Stock Option (Right to Buy) 01 Aug 2023 Common Stock 14,669 $1.17 Direct F2
holding ALUR Contingency Shares 01 Aug 2023 Common Stock 483,097 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This options is fully vested.
F2 This option shall vest and become exercisable in monthly installments over a period of 48 months from January 1, 2020, subject to the Reporting Person's continued service on each such vesting date.
F3 Subject to the terms and conditions pursuant to that certain Business Combination Agreement ("BCA") dated as of February 9, 2023, as amended on May 2, 2023, by and among Compute Health Acquisition Corp., Compute Health Corp., Compute Health LLC, the Issuer (fka Allurion Technologies Holdings, Inc.), and Allurion Technologies, Inc. ("Private Allurion"), the contingent right to receive shares of Common Stock ("Contingency Shares"), was issued as follows: one-half of the Contingency Shares, in the aggregate, if, from the period beginning on the date on which the Issuer's registration statement on Form S-1 with respect to the resale of any Common Stock issued pursuant to the PIPE Financing is declared effective by the SEC until the date which is five calendar years after the Closing Date ("Earnout Period"),
F4 (Continued from footnote 3) the VWAP is greater than or equal to $15.00 over any 20 trading days within any consecutive 30 trading day period ("First Share Target"); and one-half of the Contingency Shares, in the aggregate, if, during the Earnout Period, the VWAP is greater than or equal to $20.00 over any 20 trading days within any consecutive 30 trading day period ("Second Share Target").

Remarks:

Exhibit 24 - Power of Attorney